Company intelligence / Profile preview

Daewon Pharm

Seongdong-gu, Seoul, South Korea

Ownership: Private
Employees: ~1176
Development stage: Commercial

Overview

Daewon Pharm has over two hundred pharmaceutical products on the market across a wide range of therapeutic areas. Its most notable recent innovation includes Pelubi Tab, an NSAID developed as a new drug for degenerative joint disease. The company continues to invest heavily in R&D with pipeline candidates targeting hyperlipidemia and other indications using both synthetic chemistry and biotechnology approaches. It exports to about forty countries globally.

Therapeutic areas: PulmonologyPsychiatryRheumatologyNeurologyGastroenterologyCardiovascularNephrology
Modalities: small moleculesnatural products/biomedicinemedical supplies/devices
Industry: Biotech

Drug pipeline

45 assets

pelubiprofen

44 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Daewon Pharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Daewon Pharm.

Explore the full profile